NBTXR3 First in Class Radioenhancer

Physical Mode of Action that could work across all solid tumors to enhance radiotherapy efficacy.

Only one administration

Fits into existing standard of care:

  • No change in equipment
  • No change in current patient flow
  • No change in protocol
  • One product addressing areas of high unmet medical needs.

    See more

    Recent Press Releases

    Nanobiotix Provides Corporate Update and Highlights Key 2022 Milestone Targets
    Nanobiotix Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer
    Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 2022



    January 10

    Biotech Showcase™

    More info
    September 13

    H.C. Wainwright 23rd Annual Global Investment Conference

    More info


    “Being part of Nanobiotix is a privilege. The privilege of exploring beyond the edge of science and challenging established and existing limits for the good of humankind. The privilege of being part of an extraordinary adventure to enable people to live a better life. The privilege of expanding life.”

    Anne-Juliette Hermant
    Chief People Officer

    Download our latest
    Corporate Presentation